Global Neurology Expert Joins the Board of World’s Leading Drowsiness & Alertness Detection Company, Optalert

Optalert, the world’s leader in drowsiness and alertness detection, today welcomed Professor Matthew Kiernan as a new Non- Executive Director of its board. Professor Matthew Kiernan is Co-Director of the Brain and Mind Centre, focusing on discovery and translation and President of the Brain Foundation, funding world-class research into neurological disorders, brain disease and brain...
September is World Alzheimer’s month, the international campaign which raises awareness and challenges the stigma that surrounds dementia. Around the world 50 million people have dementia, and each year there are nearly 10 million new cases. The total number of people with dementia is projected to reach 82 million by 2030! With over 100 forms...
  BIO International Convention is back in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Optalert look forward to joining the global biotech community during partnering sessions and will be available for meetings through the official Bio2019 partnering portal, opening...
The Consumer Electronics Show (CES2019) dazzled participants once again with glimpses of technologies and products on the horizon for the future.  With over 180,000 attendees from 150 different countries, circulating over 11 venues throughout Las Vegas. Optalert’s key conversations at this year’s event included autonomous vehicles, enhanced ‘early warning’ drowsiness and distraction features, and AI...
Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject.  By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness.  Utilising the Johns Drowsiness Scale (JDS), Optalert’s future-proofed...
Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is...

Search

Categories

Categories

Date

Date

Search

Categories

Categories

Date

Date